About

CBD Wire covers UK CBD, on the record. The British market is unusual: it runs on a novel-foods regime with a public register, a per-container limit on controlled cannabinoids, and a regulator that publishes its working. Most coverage of CBD ignores all of that. We think it is the story — because it is the part a buyer can actually check.

What we cover

Two things, in roughly equal measure. News: what the Food Standards Agency and the wider regulatory machinery are doing, reported with dates and sources and without panic — the public list, the authorisation process, the rules that decide what may sit on a UK shelf. Reviews: UK CBD brands judged on the things that can be verified — their position on the FSA’s public list, their published lab reports, the clarity of their labels, and what a milligram of CBD actually costs once you do the arithmetic. Effects are reported as “marketed for” or “users report”; we are not doctors and CBD foods are not medicines, and we never pretend otherwise.

How this site is funded

CBD Wire is an independent, commercially supported publication. Some links on this site — clearly marked — may earn us affiliate commissions or advertising revenue. That revenue keeps the site running; it does not dictate a single conclusion. Verdicts, scores, and cons lists are written before anyone thinks about links, and a brand cannot buy a kinder one at any price. The editorial policy spells out how that works in practice, and it applies to every page here.

Who edits it

The site is edited under the byline Gemma Hartley — a disclosed house pen name maintained by the editorial team, in the tradition of publications that write under a house identity. Reviews run under that byline; news runs under “Staff, CBD Wire”. We explain the model plainly on the editorial policy page because we would rather tell you than have you wonder. Corrections, questions, and tips reach the desk via the contact page, where a person reads them.